tiprankstipranks
Trending News
More News >

Processa Pharmaceuticals Raises $5M in Public Offering

Story Highlights
Processa Pharmaceuticals Raises $5M in Public Offering

Confident Investing Starts Here:

Processa Pharmaceuticals ( (PCSA) ) has issued an announcement.

On January 27, 2025, Processa Pharmaceuticals entered into a securities purchase agreement with a healthcare-focused institutional investor, resulting in the sale of shares and warrants in a public offering. The offering closed on January 29, 2025, raising approximately $5 million in gross proceeds, which the company intends to use for general corporate purposes, marking a significant financial move within the industry.

More about Processa Pharmaceuticals

Processa Pharmaceuticals is a clinical-stage pharmaceutical company focusing on developing Next Generation Chemotherapy (NGC) drugs designed to enhance safety and efficacy. These drugs are modifications of existing FDA-approved oncology therapies that alter metabolism or distribution while maintaining cancer-killing mechanisms.

YTD Price Performance: -34.22%

Average Trading Volume: 393,831

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $2.18M

For detailed information about PCSA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App